. 2023 Dec 7;12(24):21592–21604. doi: 10.1002/cam4.6693

TABLE 4.

Univariate and multivariate analysis in OS, DFS, RR, and NRM for t(8;21)‐AML.

	OS		DFS		RR		NRM
	Univariate analysis	Multivariate analysis	Univariate analysis	Multivariate analysis	Univariate analysis	Multivariate analysis	Univariate analysis	Multivariate analysis
Age	0.000	0.040	0.000	0.037	0.008	0.239	0.009	0.379
Sex	0.396		0.594		0.392		0.891
Activating kinase	0.163		0.023	0.000	0.021	0.014	0.596
Chromatin modifier	0.644		0.927		0.458		0.357
Transcription factor	0.311		0.900		0.642		0.450
Cohesin	NA		NA		NA		NA
DNA methylation	0.998		0.845		0.507		0.264
Tumor suppressor	0.165		0.393		0.624		0.066
Spliceosome	NA		NA		NA		NA
Kit_mut	0.048	0.007	0.208		0.204		0.545
Flt3_mut	0.518		0.430		0.057	0.869	0.286
WT1_mut	0.108	0.011	0.260		0.763		0.046	0.008
Autosomal abnormalities	0.696		0.745		0.701		0.362
Sex chromosome abnormalities	0.169		0.05	0.360	0.368		0.063	0.970
Complex karyotype	0.239		0.620		0.832		0.285
WBC	0.410		0.615		0.373		0.364
HGB	0.964		0.267		0.283		0.682
PLT	0.297		0.845		0.344		0.364
BM blasts	0.029	0.251	0.06	0.421	0.684		0.071	0.920
Extramedullary involvement	0.480		0.392		0.519		0.598
CNS leukemia	0.702		0.904		0.953		0.880
ELN	0.367		0.671		0.995		0.478
ECOG PS	0.016	0.128	0.059	0.298	0.495		0.035	0.460
Type of AML	0.452		0.702		0.319		0.557
Induction therapy	0.057	0.202	0.003	0.003	0.083	0.020	0.025	0.091
Consolidation therapy	0.000	0.536	0.000	0.801	0.025	0.992	0.014	0.888

Abbreviations: BM, bone marrow; CNS, central nervous system; DFS, disease free survival; HGB, hemoglobin; Mut, mutation; NRM, non‐relapse mortality; OS, overall survival; PLT, platelets; RR, recurrence rate; WBC, white blood cell.